Oxnard et al conducted a retrospective analysis comparing osimertinib efficacy guided by either plasma or tissue genotyping for advanced EGFR‐mutant NSCLC.5 In that study, the reported ORR and median PFS results for the patients with T790M‐positive plasma (ORR, 63%; PFS, 9.7 months) and the patients with T790M‐positive tumor (ORR, 62%; PFS, 9.7 months) samples were similar. This evidence concerns the gene EGFR and neoplasm.